EGFR and non-small cell lung carcinoma: It has been very well documented that in the case of NSCLC progression, most mutations are associated with pathways related to the activation of the epidermal growth factor receptor protein (EGFR)—i.e., RAS/RAF/MEK/ERK and PI3K, as well as AKT/mTOR.